GLPG3312 (Compound 28), characterized as a selective pan-SIK inhibitor, exhibits IC50 values of 2.0 nM for SIK1, 0.7 nM for SIK2, and 0.6 nM for SIK3. Demonstrating both anti-inflammatory and immunomodulatory activities, this compound effectively targets human primary myeloid cells in vitro and mouse models in vivo. With favorable oral bioavailability, GLPG3312 serves as a promising agent for the study of inflammatory and immune diseases [1].